Compare FirstEnergy Corp. (FE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs 10X Genomics Inc — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.80B), while 10X Genomics Inc trades at $79.5 (market cap $9.92B). The key difference: FirstEnergy Corp. is far larger — about 2.6× 10X Genomics Inc's market cap, and FirstEnergy Corp. pays a 4.17% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and 10X Genomics Inc for 92 Days on average.
| FE | TXG | |
|---|---|---|
Market Cap | $25.80B | $9.92B |
Volume | 5,328,616 | 9,372,166 |
Sector | Utilities | Health |
52-Week High | $51.91 | $97.74 |
52-Week Low | $43.04 | $11.48 |
Typical Hold Time | 71 Days | 92 Days |
Enterprise Value | $54.72B | $9.44B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.85, up 1.33% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q1 2026 EPS beat but missed Q4 2025 and Q2 2026 expectations, with Q3 2026 results pending. Revenue grew to $15.09B in 2025 with stable profit margins around 6.86%. Recent developments include the $36B Energize365 investment plan and consistent dividend payments, supporting long-term growth prospects in the utility sector.
FE presents a moderate buy opportunity with analyst consensus target of $52.80 offering 17.7% upside. Strong institutional interest and dividend stability balance execution risks from heavy capital expenditures and debt levels. The stock's valuation appears reasonable with P/E of 23.84, though investors should monitor earnings consistency and regulatory developments in the electric utility space.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
